Figures & data
![](/cms/asset/56669307-8f7a-4371-80f0-1445945f2ae2/ianb_a_1652628_uf0001_c.jpg)
Figure 1. (i) XRD analysis of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites and (ii) Thermogravimetric analysis (TGA) of Cm-Au-PLGA-PSPE nanocomposites: (a) PLGA, (b) PLGA-PSPE and (c) Cm-Au-PLGA-PSPE.0.
![Figure 1. (i) XRD analysis of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites and (ii) Thermogravimetric analysis (TGA) of Cm-Au-PLGA-PSPE nanocomposites: (a) PLGA, (b) PLGA-PSPE and (c) Cm-Au-PLGA-PSPE.0.](/cms/asset/d56f1dae-49b9-45c6-88c0-74d67d65a74e/ianb_a_1652628_f0001_c.jpg)
Figure 2. FTIR spectra of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites. (a) PLGA, (b) PLGA-PSPE, (c) Au-PLGA-PSPE, (d) Cm and (e) Cm-Au-PLGA-PSPE.
![Figure 2. FTIR spectra of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites. (a) PLGA, (b) PLGA-PSPE, (c) Au-PLGA-PSPE, (d) Cm and (e) Cm-Au-PLGA-PSPE.](/cms/asset/50a1215c-8ba5-4279-9919-8959ae8adaa0/ianb_a_1652628_f0002_c.jpg)
Figure 3. (A) UV-vis spectroscopy of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites recorded at different wavelengths. (B) Dynamic light scattering (DLS) analysis of Cm-Au-PLGA-PSPE showing the particle size of nanocomposites.
![Figure 3. (A) UV-vis spectroscopy of carmustine (Cm) gold co-loaded with PLGA-PSPE nanocomposites recorded at different wavelengths. (B) Dynamic light scattering (DLS) analysis of Cm-Au-PLGA-PSPE showing the particle size of nanocomposites.](/cms/asset/f791f864-10ad-4226-bdb1-bc8e79dc2d23/ianb_a_1652628_f0003_c.jpg)
Figure 4. Scanning electron microscopy and transmission electron microscopy of Cm-Au-PLGA-PSPE nanocomposites.
![Figure 4. Scanning electron microscopy and transmission electron microscopy of Cm-Au-PLGA-PSPE nanocomposites.](/cms/asset/c5419c24-5ff4-4783-9230-a5c5ac3329fc/ianb_a_1652628_f0004_c.jpg)
Figure 5. Drug entrapment efficiency (A) and drug release potential (B) of Cm-Au-PLGA-PSPE nanocomposites.
![Figure 5. Drug entrapment efficiency (A) and drug release potential (B) of Cm-Au-PLGA-PSPE nanocomposites.](/cms/asset/f3eba909-d9f7-488b-8969-775539661959/ianb_a_1652628_f0005_b.jpg)
Figure 6. Drug active potential at different temperature (A) and cell viability of U251 human glioma (B) after treatment with Cm-Au-PLGA-PSPE nanocomposites.
![Figure 6. Drug active potential at different temperature (A) and cell viability of U251 human glioma (B) after treatment with Cm-Au-PLGA-PSPE nanocomposites.](/cms/asset/7f69aa2e-75f2-4695-bf3d-e67db1c2f496/ianb_a_1652628_f0006_c.jpg)
Figure 7. Histopathological examination of normal brain tissues treated with Cm-Au-PLGA-PSPE nanocomposites. (A) treated at 10 μgmL−1 (B) treated at 50 μgmL−1 and (C) treated at 100 μgmL−1.
![Figure 7. Histopathological examination of normal brain tissues treated with Cm-Au-PLGA-PSPE nanocomposites. (A) treated at 10 μgmL−1 (B) treated at 50 μgmL−1 and (C) treated at 100 μgmL−1.](/cms/asset/22c81411-fadb-474e-8e63-68699c4e7b23/ianb_a_1652628_f0007_c.jpg)
Figure 8. Histopathological examination of human glioma cells treated with Cm-Au-PLGA-PSPE nanocomposites. (A) treated at 10 μgmL−1 (B) treated at 50 μgmL−1 and (C) treated at 100 μgmL−1.
![Figure 8. Histopathological examination of human glioma cells treated with Cm-Au-PLGA-PSPE nanocomposites. (A) treated at 10 μgmL−1 (B) treated at 50 μgmL−1 and (C) treated at 100 μgmL−1.](/cms/asset/8964b6f6-96fa-4865-b09a-063f8afef212/ianb_a_1652628_f0008_c.jpg)